tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Mural Oncology reports Q2 EPS ($2.78) vs ($1.86) last year
PremiumThe FlyMural Oncology reports Q2 EPS ($2.78) vs ($1.86) last year
2M ago
Premium
Company Announcements
Mural Oncology Plc Elects Directors at Annual Meeting
4M ago
Premium
Pre-Earnings
MURA Upcoming Earnings Report: What to Expect?
5M ago
Mural Oncology price target lowered to $6 from $18 at H.C. Wainwright
PremiumThe FlyMural Oncology price target lowered to $6 from $18 at H.C. Wainwright
6M ago
Mural Oncology halting progress of nemvaleukin trial in ovarian cancer
Premium
The Fly
Mural Oncology halting progress of nemvaleukin trial in ovarian cancer
6M ago
Mural Oncology downgraded to Hold from Buy at JonesResearch
Premium
The Fly
Mural Oncology downgraded to Hold from Buy at JonesResearch
6M ago
PremiumRatingsPromising Outlook for Mural Oncology: Buy Rating Driven by Nemvaleukin’s Potential and Strategic Trials
7M ago
Premium
Company Announcements
Mural Oncology Highlights 2024 Financial Results and Strategic Focus
7M ago
Mural Oncology reports Q4 EPS ($2.01), consensus ($1.96)
Premium
The Fly
Mural Oncology reports Q4 EPS ($2.01), consensus ($1.96)
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100